2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 973

Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Abstract Number: 1368

Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease
Abstract Number: 1357

Clinical Description of Patients with Cytoplasmic Discrete Speckles on Indirect Immunofluorescence on HEp-2 Cells in a Universitary Hospital
Abstract Number: 649

Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study
Abstract Number: 3008

Clinical Factors Associated with Non-Response to Methotrexate in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Response to Treatment Consortium
Abstract Number: 1954

Clinical Features and Long Term Outcome of 105 Patients of Granulomatosis with Polyangiitis: A Single Centre Experience from North India
Abstract Number: 904

Clinical Features and Mortality of 411 Chinese Takayasu’s Arteritis Patients
Abstract Number: 1924

Clinical Features and Outcome in Patients with Elderly Onset ANCA Associated Vasculitis
Abstract Number: 1316

Clinical Features and Outcomes of Prosthetic Joint Septic Arthritis: The Gender Effect
Abstract Number: 1546

Clinical Features at the Onset of Lymphoproliferative Disorder in Patients with Rheumatoid Arthritis
Abstract Number: 901

Clinical Features of Takayasu’s Arteritis from an Inception Cohort: Early Disease Is Characterized By ‘systemic Inflammation’
Abstract Number: 2677

Clinical Features of Primary Sjogren’s Syndrome Associated Lung Involvement with Extro-Glandular Manifestations at Onset
Abstract Number: 1801

Clinical Implications of Persistent Sinus Tachycardia in Systemic Lupus Erythematous: A Retrospective Study
Abstract Number: 2887

Clinical Predictors for Development of Interstitial Lung Disease in Mixed Connective Tissue Disease
Abstract Number: 223

Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].